New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.46+0.30 (+1.75%)
At close: 04:00PM EDT
17.22 -0.24 (-1.37%)
After hours: 07:28PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 530.97M
Enterprise value 861.00M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.50
Price/book (mrq)44.19
Enterprise value/revenue 2.32
Enterprise value/EBITDA -43.75

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 37.12%
S&P500 52-week change 3-7.05%
52-week high 322.36
52-week low 311.60
50-day moving average 316.87
200-day moving average 316.17

Share statistics

Avg vol (3-month) 31.06M
Avg vol (10-day) 3908.43k
Shares outstanding 529.71M
Implied shares outstanding 6N/A
Float 824.72M
% held by insiders 14.30%
% held by institutions 196.90%
Shares short (28 Apr 2022) 47.99M
Short ratio (28 Apr 2022) 411.87
Short % of float (28 Apr 2022) 438.02%
Short % of shares outstanding (28 Apr 2022) 426.89%
Shares short (prior month 30 Mar 2022) 48.24M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin -18.44%
Operating margin (ttm)-9.95%

Management effectiveness

Return on assets (ttm)-4.50%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)370.39M
Revenue per share (ttm)11.94
Quarterly revenue growth (yoy)8.50%
Gross profit (ttm)360.37M
EBITDA -34.36M
Net income avi to common (ttm)-68.29M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)395.7M
Total cash per share (mrq)13.32
Total debt (mrq)725.73M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.16
Book value per share (mrq)-12.51

Cash flow statement

Operating cash flow (ttm)-7.11M
Levered free cash flow (ttm)13.02M